Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
Wegovy demonstrated a 20% reduction in the risk of major cardiovascular adverse events and a 19% reduction in the risk of all-cause death in the SELECT trial. The approval extends Novo Nordisk's leadership position in the obesity market and makes Wegovy eligible for Medicare coverage. Wegovy's cardiovascular benefits and Medicare coverage could contribute significant revenue growth for Novo Nordisk in the coming years. Novo Nordisk A/S NVO ) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events ('MACE') in early March. Novo Nordisk is already enjoying significant commercial success Recommended For You Recommended For You About NVO Stock More on NVO Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme [Yahoo! Finance]Yahoo! Finance
- Congruence Therapeutics Appoints Experienced Drug Developer Michael D. Harvey, Ph.D. as Chief Development Officer [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor [Yahoo! Finance]Yahoo! Finance
- 21st.BIO unveils a new pilot plant facility to accelerate impact of biotech innovations globally [Yahoo! Finance]Yahoo! Finance
- Three health foundations tackle biggest disease threats in $300mn deal [FT.com - Mergermarket]FT.com - Mergermarket
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/6/24 - Form 6-K
- 5/6/24 - Form 6-K
- 5/6/24 - Form 6-K
- NVO's page on the SEC website